Search Results

July 21, 2017

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet

Innovative Medicine

July 13, 2017

JANSSEN ANNOUNCES U.S. FDA APPROVAL OF TREMFYA™ (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

Innovative Medicine

July 11, 2017

Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen

First in-human, Phase 1/2a data from APPROACH preventive HIV-1 vaccine clinical trial to be featured in oral presentation and included in official IAS press program. Interim results from the Phase 3 pivotal EMERALD trial investigating darunavir-based single-tablet regimen selected for oral presentation; data submitted to regulatory authorities for EMA approval, September 2017.

Innovative Medicine

June 28, 2017

U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism (VTE)

Corporate

June 20, 2017

Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson Launches Campaign for Champions of Science

Innovative Medicine

June 16, 2017

DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies

DARZALEX combination therapy offers new option for patients previously treated with two commonly used treatments (lenalidomide and a proteasome inhibitor)

Innovative Medicine

June 14, 2017

New Phase 3 Data Show Anti-TNF Alpha SIMPONI ARIA® (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis

Treatment with SIMPONI ARIA® Showed Significant Inhibition in the Progression of Structural Damage

Innovative Medicine

June 12, 2017

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program

Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions

Innovative Medicine

June 8, 2017

Janssen and Johnson & Johnson Innovation Launch Next-Gen Baby Box QuickFire Challenge in Collaboration with Sitra, Tekes and VTT

Challenge seeks ideas and solutions to celebrate 80th anniversary of Finnish Baby Box and spur innovation to promote child health and healthy parenting

Innovative Medicine

June 5, 2017

Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine